Newsroom
Spotlight Story
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Read more
Press Releases
UCB extends its BIMZELX® “Get Yourself Back” direct-to-consumer campaign for the hidradenitis…
Read More
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by…
Read More
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Read More
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of…
Read More
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (…
Read More
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular…
Read MoreUCB Stories
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Read More
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial…
Read More
Tu Salud Tu Familia Generates Awareness for Rare Diseases such as Myasthenia Gravis
Read More
Resources for Resilience: Dravet Syndrome Awareness Month for Families Living with DEEs
Read More
Partnering with Patient Communities to Advance HS Awareness and Care
Read More
